Craig Tooman Insider Sell
Craig Tooman, the CHIEF FINANCIAL OFFICER of Aratana Therapeutics Inc made unloading of 3,250 shares with an average share price of $8.1 in the Kansas-based company, that are having a worth of $26,189 US Dollars. This transaction decreased his ownership of the Company to 0.20% total market cap or 73,600 shares. Published October 2, 2015, you can read more about the trade by accessing the following original document here.
Aratana Therapeutics Inc Sentiment and Fundamentals
Nine leading security analysts covering Aratana Therapeutics Inc expect earnings for each share of $-1.36 2015, which would translate to a price to earnings ratio of NaN, and year-on-year 15.00% percent growth rate.
Chart analysis shows Aratana Therapeutics Inc’s stock price dived 33.52% in the last 200 days. And this downward trend looks set to continue. Our analysts too rate the corporation’s stock a sell mainly because of our equities trend-following model which is displayed on the chart below.
Just as well-known stock traders (who include Michael Platt) noted, the highest risk-adjusted returns are made via a mix of both fundamental as well as technical analysis.
Institutional Ownership
SEC filings showed that, 91 hedge funds and institutional investors own shares of Aratana Therapeutics Inc. The institutional ownership of the firm in Q2 2015 is high, at 81.22% of the shares outstanding. They increased by 329,031 the total shares they hold. As of that quarter these institutional and hedge funds owned 28.40 million shares. A total of 14 funds opened new positions in Aratana Therapeutics Inc and 35 increased their holdings. There were 13 funds that closed their positions and 23 that reduced them.
This stock is held by two institutional advisors in their Top 10 stock holdings. They are: Mpm Asset Management Llc, Sio Capital Management Llc.
Geneva Advisors Llc had the greatest investment with ownership of 24,329 shares as of Q2 2015 for 0.01% of the fund’s portfolio. Mpm Asset Management Llc is another bullish institutional manager possessing 2.12 million shares of the company or 5.36% of their stocks portfolio. In addition Sio Capital Management Llc have 3.02% of their stock portfolio invested in the stock for 404,738 shares. The New York-based fund Awm Investment Company Inc. revealed it had purchased a stake worth 1.29% of the fund’s stock portfolio in Aratana Therapeutics Inc. The New York-based fund Broadfin Capital Llc is also an optimist about the -listed company, with ownership of 1.13 million shares or 0.92% of their stock portfolio.
Aratana Therapeutics NASDAQ:PETX Company Profile
Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs, or both. The Company’s target indications include pain and inflammation associated with osteoarthritis, inappetence, post-operative pain, lymphoma, osteosarcoma, atopic dermatitis, ocular herpes and feline immunodeficiency virus. The Company’s most advanced products from a development and commercialization perspective, AT-004 and AT-005, are monoclonal antibodies (MAbs) for treating lymphoma in dogs.
Company Website: Aratana Therapeutics
Now its market worth is: $314.68 million and it has 37.60 million outstanding shares. The firm has 55 employees. Today there are 85.09% shareholders and the institutional ownership is 85.09%. Aratana Therapeutics Inc was founded in Delaware on 2010-12-01. The stock closed at $8.37 yesterday and it had average 2 days volume of 207752 shares. It is up from the 30 days average shares volume of 175123. Aratana Therapeutics Inc has a 52 weeks low of $7.58 and a 52weeks high of $20.63. The current price is below the 200 days SMA. Aratana Therapeutics Inc last issued its quarterly earnings report on 08/06/2015. The company reported -0.23 EPS for the quarter, above the consensus estimate of -0.38 by 0.15. The company had a revenue of 230,000 for 6/30/2015 and 156,000 for 3/31/2015. Therefore, the revenue was 74,000 up.
Craig Tooman is also Vice President of Enzon Pharmaceuticals Inc, Ilex Oncology Inc, director of Insite Vision Inc.
* The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 25 - 2015 - and represents shares sold to cover tax liability incident to the vesting of shares of restricted stock.
